Feasibility of Prioritizing Drug–Drug-Event Associations Found in Electronic Health Records

Drug Safety

Volumn 39, Issue 1, 2016, Pages 45-57

  Banda, Juan M ^a   Callahan, Alison ^a   Winnenburg, Rainer ^a   Strasberg, Howard R ^b   Cami, Aurel ^c,d   Reis, Ben Y ^c,d   Vilar, Santiago ^e   Hripcsak, George ^e   Dumontier, Michel ^a   Shah, Nigam Haresh ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wolters Kluwer Health   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ATENOLOL; CARBOPLATIN; CARDIOVASCULAR AGENT; CARVEDILOL; CENTRAL NERVOUS SYSTEM AGENTS; CISPLATIN; CYCLOPHOSPHAMIDE; DERMATOLOGICAL AGENT; DIGOXIN; GASTROINTESTINAL AGENT; GEMFIBROZIL; GLIMEPIRIDE; HORMONE DERIVATIVE; RESPIRATORY TRACT AGENT; SIMVASTATIN; SPIRONOLACTONE; THALIDOMIDE; URINARY TRACT AGENT; WARFARIN;

ARTICLE; ASSOCIATION; BRADYCARDIA; DATA ANALYSIS; DATA MINING; DRUG DATABASE; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; LONG QT SYNDROME; NEUTROPENIA; PANCYTOPENIA; PARKINSONISM; PRIORITY JOURNAL; RHABDOMYOLYSIS; SEROTONIN SYNDROME; DRUG INTERACTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; FEASIBILITY STUDY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA MINING; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORDS; FEASIBILITY STUDIES; HUMANS;

EID: 84954364324     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0352-2     Document Type: Article

References (43)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash, DC 1996). 2001;41(2):192–9.
2. Lucado J PK, Elixhauser A. HCUP National Emergency Department Sample (NEDS) - HCUP Statistical Brief #109. Agency for Healthcare Research and Quality. 2012. http://psnet.ahrq.gov/resource.aspx?resourceID=21786
3. Becker ML, Kallewaard M, Caspers PWJ, Visser LE, Leufkens HGM, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.
4. Kiran P. Typical drug interactions in oncology. US Pharm. 2011;36(1):7–9.
5. Zhang L, Zhang Y, Zhao P, Huang S-M. Predicting drug–drug interactions: an FDA perspective. AAPS J. 2009;11(2):300–6.
6. Triaridis S, Tsiropoulos G, Rachovitsas D, Psillas G, Vital V. Spontaneous haematoma of the pharynx due to a rare drug interaction. Hippokratia. 2009;13(3):175–7.
7. Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc JAMIA. 2009;16(3):328–37.
8. Harpaz R, Perez H, Chase HS, Rabadan R, Hripcsak G, Friedman C. Biclustering of adverse drug events in FDA’s spontaneous reporting system. Clin Pharmacol Ther. 2011;89(2):243–50.
9. Haerian K, Varn D, Vaidya S, Ena L, Chase HS, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther. 2012;92(2):228–34.
10. LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther. 2013;93(6):547–55.
11. Lependu P, Iyer SV, Fairon C, Shah NH. Annotation analysis for testing drug safety signals using unstructured clinical notes. J Biomed Semant. 2012;3(Suppl 1):S5.
12. Liu M, McPeek Hinz ER, Matheny ME, Denny JC, Schildcrout JS, Miller RA, et al. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. J Am Med Inform Assoc. 2013; 20(3):420–6. doi:10.1136/amiajnl-2012-001119.
13. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–27.
14. Nadkarni PM. Drug safety surveillance using de-identified EMR and claims data: issues and challenges. J Am Med Inform Assoc JAMIA. 2010;17(6):671–4.
15. Shetty KD, Dalal S. Using information mining of the medical literature to improve drug safety. J Am Med Inform Assoc. 2011; 18(5):668–674. doi:10.1136/amiajnl-2011-000096.
16. Duke JD, Han X, Wang Z, Subhadarshini A, Karnik SD, Li X, et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol. 2012;8(8):e1002614.
17. Gottlieb A, Stein GY, Oron Y, Ruppin E, Sharan R. INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol Syst Biol. 2012;8:592.
18. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31-ra31.
19. Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug–drug interactions. J Am Med Inform Assoc. 2014;21(2):353–62.
20. Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinform. 2010;11(Suppl 9):S7-S.
21. Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA adverse event reporting system, aers, and reproducibility of clinical observations. Int J Med Sci. 2012;9(1):33–9.
22. Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug–drug interactions in adverse event reports. J Am Med Inform Assoc JAMIA. 2012;19(1):79–85.
23. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug–drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64(4):489–95.
24. van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000;56(9–10):733–8.
25. Bauer-Mehren A, van Mullingen EM, Avillach P, Carrascosa MdC, Garcia-Serna R, Piñero J, et al. Automatic filtering and substantiation of drug safety signals. PLoS Comput Biol. 2012;8(4):e1002457.
26. Vilar S, Harpaz R, Uriarte E, Santana L, Rabadan R, Friedman C. Drug–drug interaction through molecular structure similarity analysis. J Am Med Inform Assoc. 2012;19(6):1066–74.
27. Vilar S, Uriarte E, Santana L, Tatonetti NP, Friedman C. Detection of drug–drug interactions by modeling interaction profile fingerprints. PLoS One. 2013;8(3):e58321.
28. Vilar S, Uriarte E, Santana L, Lorberbaum T, Hripcsak G, Friedman C, et al. Similarity-based modeling in large-scale prediction of drug–drug interactions. Nat Protoc. 2014;9(9):2147–63.
29. Vilar S, Harpaz R, Santana L, Uriarte E, Friedman C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One. 2012;7(7):e41471.
30. Liu M, Wu Y, Chen Y, Sun J, Zhao Z, X-w Chen, et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc JAMIA. 2012;19(e1):e28–35.
31. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(Database issue):D1091-D7.
32. Callahan A, Cruz-Toledo J, Ansell P, Dumontier M. Bio2RDF release 2: improved coverage, interoperability and provenance of life science linked data. In: Cimiano P, Corcho O, Presutti V, Hollink L, Rudolph S, editors. The semantic web: semantics and big data. lecture notes in computer science. 7882: Springer Berlin Heidelberg; 2013. p. 200–12.
33. Avillach P, Dufour J-C, Diallo G, Salvo F, Joubert M, Thiessard F, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU–ADR project. J Am Med Inform Assoc JAMIA. 2013;20(3):446–52.
34. Cami A, Manzi S, Arnold A, Reis BY. pharmacointeraction network models predict unknown drug–drug interactions. PLoS One. 2013;8(4):e61468.
35. Organization WH. Anatomical Therapeutic Chemical (ATC) classification system [cited 2015 May 1st]. http://www.whocc.no/atc/structure_and_principles/. Accessed 1 May 2015.
36. Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug–drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–17.
37. Index R-TID. Drug interactions with atenolol oral and spironolactone oral [cited 2015 August 10th]. http://www.rxlist.com/drug-interactions/atenolol-oral-and-spironolactone-oral-interaction.htm. Accessed 10 Aug 2015.
38. Information e-Ph. Review: taking Spironolactone and Atenolol together [cited 2015 August 10th]. Available from: http://www.ehealthme.com/drug-interactions/atenolol-and-spironolactone. Accessed 10 Aug 2015.
39. Information e-Ph. From FDA reports: drug interactions between Glimepiride, Spironolactone for a female patient aged 73 [cited 2015 August 10th]. http://www.ehealthme.com/Spironolactone-Glimepiride-3847893. Accessed 10 Aug 2015.
40. Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother. 2002;36(5):820–3.
41. Gottlieb A, Hoehndorf R, Dumontier M, Altman RB. Ranking adverse drug reactions with crowdsourcing. J Med Internet Res. 2015;17(3):e80.
42. Scheife R, Hines L, Boyce R, Chung S, Momper J, Sommer C, et al. Consensus recommendations for systematic evaluation of drug–drug interaction evidence for clinical decision support. Drug Saf. 2015;38(2):197–206.
43. Boyce RD, Ryan PB, Norén GN, Schuemie MJ, Reich C, Duke J, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 2014;37(8):557–67.